PMID- 21951567
OWN - NLM
STAT- MEDLINE
DCOM- 20120112
LR  - 20151119
IS  - 1468-2079 (Electronic)
IS  - 0007-1161 (Linking)
VI  - 95
IP  - 12
DP  - 2011 Dec
TI  - Outcomes following three-line vision loss during treatment of neovascular 
      age-related macular degeneration: subgroup analyses from MARINA and ANCHOR.
PG  - 1713-8
LID - 10.1136/bjophthalmol-2011-300471 [doi]
AB  - AIM: This study aims to assess the impact of continued ranibizumab treatment for 
      neovascular age-related macular degeneration on patients from the MARINA and 
      ANCHOR randomised clinical studies who lost >/= 3 lines of best-corrected visual 
      acuity (BCVA) at any time during the first year of treatment. METHODS: Baseline 
      characteristics, mean BCVA over time and ocular adverse events (AEs) were 
      evaluated both for patients whose BCVA loss occurred at any post-baseline visit 
      and for patients whose BCVA loss was acute. The visit when the >/= 3-line BCVA loss 
      was detected was defined as the new baseline. RESULTS: Continued monthly 
      ranibizumab treatment led to an improvement in mean BCVA from the new baseline. 
      On average, patients with acute BCVA loss gained 11.9 letters at 3 months after 
      the new baseline, compared with 0.3 letters gained with sham. No strong signals 
      were detected in patient demographics and baseline characteristics for prognostic 
      markers of BCVA loss. Furthermore, there was no pattern in the AE profile of 
      patients with acute BCVA loss to suggest that BCVA recovery could be attributed 
      to spontaneously resolving AEs. CONCLUSION: Continued ranibizumab treatment 
      appears to be beneficial for patients with neovascular age-related macular 
      degeneration who experience a >/= 3-line BCVA loss during the first year of 
      treatment.
FAU - Wolf, Sebastian
AU  - Wolf S
AD  - Department of Ophthalmology, Inselspital, University of Bern, Bern, Switzerland. 
      sebastian.wolf@insel.ch
FAU - Holz, Frank G
AU  - Holz FG
FAU - Korobelnik, Jean-Francois
AU  - Korobelnik JF
FAU - Lanzetta, Paolo
AU  - Lanzetta P
FAU - Mitchell, Paul
AU  - Mitchell P
FAU - Prunte, Christian
AU  - Prunte C
FAU - Schmidt-Erfurth, Ursula
AU  - Schmidt-Erfurth U
FAU - Weichselberger, Andreas
AU  - Weichselberger A
FAU - Hashad, Yehia
AU  - Hashad Y
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110927
PL  - England
TA  - Br J Ophthalmol
JT  - The British journal of ophthalmology
JID - 0421041
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Choroidal Neovascularization/*drug therapy/physiopathology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Macular Degeneration/*drug therapy/physiopathology
MH  - Male
MH  - Prospective Studies
MH  - Ranibizumab
MH  - Treatment Outcome
MH  - Visual Acuity
EDAT- 2011/09/29 06:00
MHDA- 2012/01/13 06:00
CRDT- 2011/09/29 06:00
PHST- 2011/09/29 06:00 [entrez]
PHST- 2011/09/29 06:00 [pubmed]
PHST- 2012/01/13 06:00 [medline]
AID - bjophthalmol-2011-300471 [pii]
AID - 10.1136/bjophthalmol-2011-300471 [doi]
PST - ppublish
SO  - Br J Ophthalmol. 2011 Dec;95(12):1713-8. doi: 10.1136/bjophthalmol-2011-300471. 
      Epub 2011 Sep 27.